Research Paper Volume 16, Issue 4 pp 3332—3349
Machine learning constructs a T cell-related signature for predicting prognosis and drug sensitivity in ovarian cancer
Figure 7. T cell-related signature (TRS)-based treatment strategy for ovarian cancer. The IC50 values of 5-Fluorouracil (A), Bortezomib (B), Cisplatin (C), Cyclophosphamide (D), Erlotinib (E), Fludarabine (F), Fulvestrant (G), Ribociclib (H) and Topotecan (I) in different risk score group of ovarian cancer.